Physician profile
Jerrick Thacker
NPI 1275275307
$2,823.40
in general payments reported to CMS, 2019-2025
23 companies · $134 in 2025
The $134 reported for 2025 was less than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $772 · 2023: $1,031 · 2024: $887 · 2025: $134.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,051.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,051.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $329.14 | 2022-2025 | Lifevest |
| Amgen INC. | $319.61 | 2022-2024 | Repatha |
| Novartis Pharmaceuticals Corporation | $314.36 | 2022-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $302.93 | 2022-2024 | Jardiance |
| Merck Sharp & Dohme LLC | $226.85 | 2023-2024 | Verquvo, Winrevair |
| Bayer Healthcare Pharmaceuticals INC. | $216.71 | 2022-2023 | |
| Kestra Medical Technology Services, INC. | $178.30 | 2022-2025 | Assure Wcd |
| Lexicon Pharmaceuticals, INC. | $128.34 | 2023-2024 | Inpefa |
| Biohaven Pharmaceutical Holding Company Ltd. | $122.39 | 2022 | |
| Novo Nordisk INC | $99.57 | 2024-2025 | Ozempic, Rybelsus |
| Lilly USA, LLC | $84.67 | 2022-2023 | Mounjaro |
| Kiniksa Pharmaceuticals, Ltd. | $74.25 | 2022-2023 | Arcalyst |
| Exact Sciences Corporation | $70.78 | 2023-2024 | Cologuard Collection Kit |
| Abbott Laboratories | $52.98 | 2024 | Assurity, Aveir |
| Biotronik INC. | $50.69 | 2022 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $50.61 | 2023-2024 | Xarelto |
| Medtronic, INC. | $38.41 | 2022 | |
| Glaxosmithkline, LLC. | $37.07 | 2024 | Trelegy Ellipta |
| Esperion Therapeutics, INC. | $33.24 | 2024 | Nexletol |
| Sanofi-Aventis U.S. LLC | $33.06 | 2023 | |
| Actelion Pharmaceuticals US, INC. | $20.11 | 2024 | Opsumit, Uptravi |
| Pfizer INC. | $19.80 | 2024 | |
| Mylan Specialty L.P. | $19.53 | 2023 | Yupelri |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jerrick Thacker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.